# Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy

> **NCT02348320** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Triple-Negative Breast Cancer
- Triple Negative Breast Neoplasms

## Interventions

- **BIOLOGICAL:** Personalized polyepitope DNA vaccine

## Key facts

- **NCT ID:** NCT02348320
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-17
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-03-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348320, "Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02348320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*